Nature Communications (Sep 2020)

Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery

  • Anders Lundin,
  • Michelle J. Porritt,
  • Himjyot Jaiswal,
  • Frank Seeliger,
  • Camilla Johansson,
  • Abdel Wahad Bidar,
  • Lukas Badertscher,
  • Sandra Wimberger,
  • Emma J. Davies,
  • Elizabeth Hardaker,
  • Carla P. Martins,
  • Emily James,
  • Therese Admyre,
  • Amir Taheri-Ghahfarokhi,
  • Jenna Bradley,
  • Anna Schantz,
  • Babak Alaeimahabadi,
  • Maryam Clausen,
  • Xiufeng Xu,
  • Lorenz M. Mayr,
  • Roberto Nitsch,
  • Mohammad Bohlooly-Y,
  • Simon T. Barry,
  • Marcello Maresca

DOI
https://doi.org/10.1038/s41467-020-18548-9
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 16

Abstract

Read online

CRISPR/Cas9 technology has revolutionised the ability of scientists to make genetically modified cells and animal models. Here, the authors make a Tet-On genetically modified mouse using the Streptococcus pyogenes Cas9 and demonstrate that it can be used for generation of mice with lung cancer.